Afatinib treatment response in advanced lung adenocarcinomas harboring uncommon mutations-Reference-Cited by-同舟云学术

Afatinib treatment response in advanced lung adenocarcinomas harboring uncommon mutations

Published:2021-09-21 Issue:21 Volume:12 Page:2924-2932
ISSN:1759-7706
Container-title:Thoracic Cancer
language:en
Short-container-title:Thorac Cancer

Author:

Li Teng¹^ORCID,Wang Shouzheng¹,Ying Jianming²,Wang Yan¹^ORCID,Hu Xingsheng¹^ORCID,Hao Xuezhi¹,Xu Ziyi¹^ORCID,Xing Puyuan¹,Li Junling¹^ORCID

Affiliation:

1. Department of Medical Oncology National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Beijing China

2. Department of Pathology National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Beijing China

Publisher

Wiley

Subject

Pulmonary and Respiratory Medicine,Oncology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/1759-7714.14156

Reference38 articles.

1. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries

2. Making the first move in EGFR-driven or ALK-driven NSCLC: first-generation or next-generation TKI?

3. Epidermal Growth Factor Receptor Mutations in Non–Small-Cell Lung Cancer: Implications for Treatment and Tumor Biology

4. A Prospective, Molecular Epidemiology Study of EGFR Mutations in Asian Patients with Advanced Non–Small-Cell Lung Cancer of Adenocarcinoma Histology (PIONEER)

5. Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC)

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Factors associated with prolonged progression‐free survival of patients treated with first‐line afatinib for advanced epidermal growth factor receptor‐mutated non‐small cell lung cancer;Thoracic Cancer;2024-01-26

2. Advances in the Diagnosis and Treatment of Advanced Non–Small-Cell Lung Cancer With EGFR Exon 20 Insertion Mutation;Clinical Lung Cancer;2023-11

3. The treatment of patients with non-small cell lung cancer carrying uncommon EGFR mutations, HER2 mutations, or brain metastases: a systematic review of pre-clinical and clinical findings for dacomitinib;Translational Cancer Research;2023-08

4. Afatinib in Untreated Stage IIIB/IV Lung Adenocarcinoma with Major Uncommon Epidermal Growth Factor Receptor (EGFR) Mutations (G719X/L861Q/S768I): A Multicenter Observational Study in Taiwan;Targeted Oncology;2023-02-20

5. A L833V/H835L EGFR variant lung adenocarcinoma with skin metastasis: A case report and literature review;Heliyon;2022-12